Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report)’s share price traded down 7.4% during trading on Wednesday . The stock traded as low as $25.00 and last traded at $25.01. 77,936 shares changed hands during trading, a decline of 62% from the average session volume of 207,198 shares. The stock had previously closed at $27.00.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. Zacks Research raised Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Evercore assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. Wedbush began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price on the stock. Finally, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Hemab Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $41.75.
Read Our Latest Stock Report on Hemab Therapeutics
Hemab Therapeutics Stock Performance
Insider Activity
In other news, major shareholder Ra Capital Management, L.P. purchased 3,802 shares of the stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $24.97 per share, with a total value of $94,935.94. Following the completion of the purchase, the insider directly owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. The trade was a 0.06% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders purchased 2,902,872 shares of company stock valued at $53,769,784 over the last quarter.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Read More
- Five stocks we like better than Hemab Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
